webinar register page

Webinar banner
BSTP/STP Webinar: Preclinical safety strategy for the development of mRNA Lipid Nano Particle-based vaccines
Speaker: Eric Jacquinet, DVM, PhD, DABT, Moderna, Inc

Abstract: The rapid development of vaccines against SARS-CoV-2, the virus responsible for the ‘coronavirus disease 2019’ (COVID-19) pandemic, exemplifies the power of mRNA technologies for vaccine development. The first human clinical trials of a COVID-19 vaccine were initiated within 4 months of the publication of the SARS-CoV-2 sequence using lipid nano-particle (LNP)-encapsulated mRNA-based vaccines engineered to encode the SARS-CoV-2 S (“Spike”) protein in its pre-fusion conformation. Antibodies against S protein epitopes can neutralize the virus. The advantages of the RNA modality are in its versatility (antigen sequences can be swapped into the constructs easily), ease of manufacturing (in vitro transcription from a DNA template), and general safety. mRNA vaccines are non-infectious and non-integrating and because the mRNA is degraded by the host within cytosol quickly, both the mRNA and antigen expression are transient. As this type of vaccine is using the same cargo (LNP) to deliver the load (mRNA), the safety profile of the different vaccines become very predictable and allow a platform-based approach and a reduced development period.

May 31, 2022 11:00 AM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Tierre Miller.